Lead is one of the most important industrial poisons and at the present time most adult cases of lead poisoning are of industrial origin. In children lead poisoning is an occasional hazard where the habit of pica may result in the ingestion of leaded paint. Rarely, sporadic or even epidemic cases may result from the consumption of drinking water transported in lead tanks and pipes, or of beverages prepared in imperfectly glazed earthenware vessels. The incidence of industrial lead poisoning has dropped sharply during the present century because of the application of vigorous preventive measures such as adequate factory ventilation, the use of masks, the pursuance of meticulous personal hygiene and possibly the provision of milk for exposed workers.
Despite these precautions it is sometimes necessary to eliminate lead by the use of chelating drugs. Two drugs are currently used as chelating agents in lead poisoning. Sodium calcium edetate, the calcium chelate of the disodium salt of ethylene tetra-acetic acid exchanges calcium to form a lead chelate which is excreted in the urine. Penicillamine, a sulpha-amino acid derived from penicillin was pioneered by Walshe and introduced by him for the treatment of hepatolenticular degeneration. Its chelating effect is due to the provision of a sulphydryl group which combines with lead (and copper) to form ring compounds which are excreted.
Penicillamine was first used for the treatment of inorganic lead poisoning by Boulding & Baker in 1957 . The first large, in-depth study of the problem was made by Goldberg et al. in Glasgow in 1963 . They reported the response in terms of clinical improvement, urinary lead, f&cal lead, urinary coproporphyrin and urinary ALA in 9 industrially lead-poisoned men treated with D-penicillamine in a dose of 750 to 1250 mg daily for up to nine weeks. A gradual rise in haemoglobin in the anemic men followed over a period of up to 120 days. These authors were also the first to observe nephrotoxic effects in lead-poisoned patients treated with penicillamine. Selander (1967) carried out a comparison of penicillamine with edetate both orally and intravenously in patients with lead poisoning. He found no significant difference in lead excretion between the use of intravenous edetate and of oral penicil-lamine. In a separate experiment he compared oral penicillamine with intramuscular penicillamine and showed a slight but significant increase in lead excretion from intramuscular penicillamine. However, the experiment confirmed that penicillamine was an effective lead chelator when given orally, and it remains the only such drug. Oral administration has clear advantages in that it can be used in outpatient treatment of the industrially exposed and it obviates the need for injections in children.
Most cases of lead poisoning are caused by the inorganic compounds of lead such as lead oxide and lead sulphate. Occasionally one sees patients with poisoning by the organic compounds of lead such as tetra-ethyl lead and tetra-methyl lead. Penicillamine is an effective chelator of these substances. Beattie et al. (1972) reported 4 patients who acquired poisoning by tetra-ethyl lead in the course of cleaning a tank which contained the leaded petrol aviation fuel Avgas, which has a lead content of approximately 1.5 g per litre. These patients had a quite different illness from those poisoned with inorganic lead in that they suffered agitation, insomnia and toxic delirium. A provocative test with Dpenicillamine, collecting urine for 24 hours to obtain a base-line and repeating it after a dose of 500 mg of penicillamine orally, showed considerably elevated basal lead levels, which increased approximately two-fold after penicillamine. The patients were then treated with D-penicillamine in a dose of 250 mg three times a day, and satisfactory lead chelation was achieved.
The influence of chelating agents on the gastrointestinal absorption of lead was studied by Jugo etal. (1975) . Theyfound that D-penicillamine given orally caused an increase in lead absorption from the bowel, and for that reason they recommended that oral D-penicillamine be avoided if a significant amount of unabsorbed lead in the bowel is suspected. This may be of some relevance in the treatment of children with pica, but in general is probably not of great clinical significance.
Environmental lead pollution is a current subject of interest and controversy, and the possible place of penicillamine in the treatment of patients, particularly children, who are environmentally exposed to large amounts of lead either from atmosphere or from water is uncertain. Such environmental lead pollution may have clinical significance in three different areas. Firstly, where the water lead content of a house 44 Proc. roy. Soc. Med. Volume 70 1977 Supplement 3 exceeds 800 ,ug/litre the chance of a child living in that house developing mental retardation is increased approximately two-fold (Beattie et al. 1975) . Secondly, hypertensive patients in a health span survey had higher domestic water leads than their normotensive controls, age and sex matched, living in the same area (Beevers et al. 1976 ); and thirdly, Campbell et al. (1977) showed that raised domestic water lead levels are significantly associated with raised blood urea and uric acid levels in a study done in conjunction with Scottish General Practitioners.
Obviously, the main answer to these environmental problems is to reduce the amount of lead in the environment, but it is possible that penicillamine may have a place in the treatment of, for example, children with raised blood lead levels and mental retardation or adults with raised blood lead levels and hypertension. This would have to be carefully balanced against the sideeffects of the drug, and as yet there is insufficient evidence to answer this question.
Conclusions
(1) Penicillamine is the only effective oral lead chelator and can be used satisfactorily in a dose of 500-1000 mg per day. (2) Dr Williams: We would suggest that zinc is also removed. Dr Beattie: From the work presented this morning this appears to be well worth doing, but we have not done it as yet.
Dr Williams: Just as edetate therapy is known to produce a deficiency of a number of trace elements, so too the computer simulation models suggest that D-penicillamine produces zinc excretion. Therefore zinc supplementation is desirable. (Incidentally, our models suggest that edetate intravenous infusions ought to consist of a 1 :3 mixture of zinc: calcium as an improvement upon pure calcium edetate).
Dr Scheinberg: It is relevant to point out that we have never seenand nor I think has Dr Walsheany indication of zinc deficiency in patients with Wilson's disease treated for years, or even decades, with penicillamine. None of us, to my knowledge, supplements that treatment with zinc. Dr Williams: May I draw your attention to a very recent report of zinc deficiency symptoms (Klingberg W G, Prasad A S & Oberleas D, 1976, in: Trace Elements in Human Health and Disease, Vol 1. Zinc and Copper, Ed. A S Prasad. Academic Press, London; pp 51-66).
Dr Moynahan: This is a case reported of zinc deficiency in a patient with Wilson's disease treated with penicillamine, in which he suffered from alopecia and psoriatiform eruptions. He also suffered a very severe permanent loss of central vision (Klingberg W G et al. 1976 ) and I have drawn attention to the role of zinc in visual behaviour as well as colour vision (Moynahan E J, 1976, Lancet ii, 91).
Dr Lyle: There was a paper recently by Simkin (1976, Lancet ii, 539) , suggesting that penicillamine worked in rheumatoid arthritis because it gave rise to a net increase in uptake of zinc. Zinc, in his view, brought about the relief ofrheumatoid symptoms. Dr Beattie: That may be a theoretical objection but, on clinical grounds, we have monitored the various factors affected by lead, such as renal function, anemia and so on, and the patients appear to get better on penicillamine, in addition to having less lead in their body.
Dr C B M Warren (Felsted): I believe that, in infants, lead can produce central nervous system signs. Would this be due to redistribution of the lead? Dr Beattie: I do not think so. Lead causes central nervous system signs much more easily in infants than in adultsthis is certainly true. Quite a number of people have now treated leadpoisoned infants with encephalopathy in this way, and the results seem to be acceptable. I do not think that good animal studies on redistribution have been done, but it seems to work on clinical grounds. Dr Warren: Can exactly the same dose be given, or a smaller dose? Dr Beattie: We have a smaller doseabout 500 mg a day to infants.
Mr P Purkiss (Harrow): Would Dr Beattie like to comment on the metabolism of lead in between being absorbed and actually being chelated? Do the organic and inorganic leads have a common intermediate anywher between being absorbed and being excreted? Dr Beattie: After absorption, lead is stored mainly in the bones, but it is also contained in measurable amounts in liver, spleen and kidney. The exact mechanism, or the site at which penicillamine either releases the lead or forms chelates, is not known.
Tetra-ethyl lead has a different metabolism in that it has an affinity for adipose tissue. It is easily absorbed through the skin and seems to attach itself mainly to nervous tissue.
Dr Brown: One thing that would worry me with this type of therapy, if I were a patient, is that another ligand is being added, in this case to lead. The lead is being redistributed in the body. It is poisonous to start with and may be even more so afterwards. I think this is something to be handled with caution, especially in the case of cadmium and other forms of poisonous metals. What we might finish up with after a redistribution is a lower concentration but in a more potent position.
